Pharmacology>Moa Identification Practice Test

A 58-year-old man with hypertension and type 2 diabetes is started on a new once-daily antihypertensive for renal protection. Two weeks later, his blood pressure has improved from 154/92 to 128/78. He reports a persistent dry cough but denies dizziness or swelling of the lips or tongue. Laboratory testing shows potassium 5.2 and a small rise in serum creatinine from 0.9 to 1.1. He takes metformin and atorvastatin, does not use NSAIDs, and has no history of heart failure. The pharmacist suspects the agent is from a class associated with cough due to bradykinin accumulation.

A 67-year-old woman presents with palpitations and dyspnea; ECG shows atrial fibrillation with rapid ventricular response (HR 148). She receives an IV bolus of a medication followed by a short infusion. Her heart rate decreases to 92, blood pressure remains 122/74, and the PR interval is modestly prolonged on telemetry. She reports mild constipation after prior oral doses of the same drug for angina. She has asthma and prefers to avoid beta-blockers when possible. The team plans to transition to an oral formulation for continued rate control.